Scientific Limits & Silicon Valley Market Dynamics
🧮 Order Statistics & Mathematical Limits
The maximum expected gain from selecting the top scoring embryo among N candidates scales with E[max X_N] ≈ h · √(2 · ln N), where h is the square root of $R^2$. Due to logarithmic growth, doubling embryo yield from 10 to 20 adds less than 15% incremental gain, presenting hard natural limits to screening standard IVF cycles.
🧬 Biological Trade-offs & Pleiotropy
Polygenic scores index thousands of variant loci. Due to negative genetic covariance ($\gamma$), optimizing aggressively for one complex trait (e.g. cardiovascular risk reduction) can inadvertently elevate risk profiles for pleiotropically linked auto-immune or neurodevelopmental phenotypes.
💼 "Catnip to Silicon Valley" Investment Reality
As reported by The Economist, venture capital is drawn to reproductive biotech due to recurring SaaS-like platform margins combined with high-LTV healthcare dynamics. However, market adoption faces severe bottlenecks in IVF cycle scalability unless stem-cell derived gametogenesis (IVG) matures.